Loading…
Loading…
WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (the "Company") today announced its intention to voluntarily file a Form 25 Notification of Delisting with the U.S. Securities and Exchange Commission (the "SEC") on Monday, April 20, 2026, to remove its common stock from listing and registration on The Nasdaq Stock Market LLC ("Nasdaq"). As previously disclosed, trading in the Company's common stock was suspended by Nasdaq on March 17, 2026. Although Nasdaq has indicated it intends to file its own Form 25 after all internal procedural periods have run, it has not yet done so. The Company is therefore voluntarily filing Form 25 in order to proceed with deregistration. The Company's common stock is currently quoted on the Pink Limited Market. This press release is being issued in compliance with Rule 12d2-2(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining more than 50 points on Monday.
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company's lead product candidate for the treatment of chronic rhinosinusitis (CRS).
Lyra Therapeutics, Inc. (NASDAQ: LYRA - Get Free Report)'s share price was up 0.3% on Friday. The stock traded as high as $3.70 and last traded at $3.59. Approximately 32,339 shares changed hands during trading, a decline of 4% from the average daily volume of 33,546 shares. The stock had previously closed at $3.58. Analysts
Lyra Therapeutics, Inc. (NASDAQ: LYRA - Get Free Report)'s share price was up 4.5% on Wednesday. The stock traded as high as $4.32 and last traded at $4.19. Approximately 48,758 shares traded hands during mid-day trading, a decline of 48% from the average daily volume of 94,587 shares. The stock had previously closed at $4.01.
Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $3.38 per share versus the Zacks Consensus Estimate of a loss of $5.98. This compares to a loss of $9 per share a year ago.
– Company plans new, confirmatory Phase 3 clinical trial of LYR-210 for treatment of chronic rhinosinusitis (CRS) without nasal polyps, on path to NDA submission –
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a late clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced the Company's clinical plan and upcoming oral presentation of results from the positive Phase 3 ENLIGHTEN 2 trial for LYR-210, the company's lead product candidate for CRS.